Anti-Human CD257 (BAFF) (Tabalumab) - PE Biosimilar (IVMB0442)
- SKU:
- IVMB0442
- Antibody Type:
- PE Biosimilar
- Modifications:
- PE-Conjugated
- Applications:
- IHC
- FC
- Drug Development
- Pharmacokinetics
- Disease Area:
- Cancer
Description
| Product Name: | Anti-Human CD257 (BAFF) (Tabalumab) - PE |
| SKU: | IVMB0442 |
| Size: | 50 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | Tabalumab |
| Target: | BAFF |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human/Cynomolgus Monkey/Rabbit |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | Tabalumab, CD257, BAFF, TNFSF13b, BLYS |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm) |
| Immunogen: | Original antibody was raised against soluble human BAFF. |
| Antigen Distribution: | BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells. |
| Formulation: | This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only. |
| Additional Reported Applications For Relevant Conjugates: | NIPWBELISA |
Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects.
| Ligand/Receptor: | TACI, BCMA,APRIL ligand, BAFFR/BR3 |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C.Do not freeze. |
| UniProt: | Q9Y275 |
| Research Area: | Biosimilars |
Related Products
Anti-Human CD257 (BAFF) (Tabalumab) - Biotin Biosimilar (IVMB0441)
VivoGenie Anti-CD257 / BAFF (Tabalumab) Biosimilar (IVMB0213)
Anti-Human CD257 (BAFF) (Tabalumab) - Dylight® 488 Biosimilar (IVMB0445)
Anti-Human CD257 (BAFF) (Tabalumab) - Fc Reduced Biotin Biosimilar (IVMB0443)
